Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

A randomized controlled trial of intravenous tissue plasminogen-activator and early intravenous heparin in acute myocardial-infarction

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Topol, Eric
  • George, B. S.
  • Kereiakes, D. J.
  • Stump, D. C.
  • Candela, R. J.
  • Abbottsmith, C. W.
  • Aronson, L.
  • Pickel, A.
  • Boswick, J. M.
  • Lee, K. L.
  • Ellis, S. G.
  • Califf, R. M.

publication date

  • February 1989

journal

  • Circulation  Journal

abstract

  • To evaluate the coronary thrombolytic efficacy of tissue plasminogen activator (t-PA) and early intravenous heparin, 134 patients with acute myocardial infarction were randomly assigned to combination therapy or t-PA only. At a median of 2.78 hours from symptom onset, 64 patients received both t-PA (1.5 mg/kg/4 hr) and a bolus of 10,000 units heparin, whereas 70 patients received t-PA alone at the same dose. All patients underwent coronary angiography 90 minutes after initiation of therapy to determine infarct vessel patency status, after which time the control group patients were eligible to receive heparin. Baseline demographic and angiographic characteristics were similar for the groups. Infarct vessel patency was 50 of 63 (79%) for combination t-PA and heparin and 54 of 68 (79%) for t-PA alone. Bleeding complications, as reflected by need for transfusion, were similar in the two groups: 13% in the patients treated with t-PA and heparin compared with 18% in patients treated with t-PA only (p = 0.53). The only intracranial hemorrhage in the trial occurred in a patient initially treated without heparin. Fibrinogen at 50 minutes after therapy was 32% decreased from baseline for the t-PA and heparin-treated patients compared with a 39% decrease in the control group. Predischarge left ventricular ejection fraction was similar for the two groups: 49.0 +/- 10.1% versus 50.2 +/- 11.9% for combined versus t-PA only therapy, respectively. We conclude that early intravenous heparin does not facilitate the fibrinolytic effect of t-PA at the doses tested.(ABSTRACT TRUNCATED AT 250 WORDS)

subject areas

  • Angiography
  • Clinical Trials as Topic
  • Drug Therapy, Combination
  • Heparin
  • Humans
  • Injections, Intravenous
  • Myocardial Infarction
  • Random Allocation
  • Time Factors
  • Tissue Plasminogen Activator
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0009-7322

PubMed ID

  • 2492454
scroll to property group menus

Additional Document Info

start page

  • 281

end page

  • 286

volume

  • 79

issue

  • 2

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support